Cargando…
CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer
BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer with a dismal prognosis. Although combined treatment with gemcitabine and albumin-bound paclitaxel has improved the prognosis of PDAC, both intrinsic and acquired chemoresistance remain as severe hurtles towards improved pro...
Autores principales: | Zeng, Siyuan, Lan, Bin, Ren, Xiaofan, Zhang, Shuman, Schreyer, Daniel, Eckstein, Markus, Yang, Hai, Britzen-Laurent, Nathalie, Dahl, Andreas, Mukhopadhyay, Debabrata, Chang, David, Kutschick, Isabella, Pfeffer, Susanne, Bailey, Peter, Biankin, Andrew, Grützmann, Robert, Pilarsky, Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9364549/ https://www.ncbi.nlm.nih.gov/pubmed/35945614 http://dx.doi.org/10.1186/s13046-022-02443-w |
Ejemplares similares
-
CRISPR-Cas9 Screen Identifies DYRK1A as a Target for Radiotherapy Sensitization in Pancreatic Cancer
por: Lan, Bin, et al.
Publicado: (2022) -
Identification of Genes Associated with Liver Metastasis in Pancreatic Cancer Reveals PCSK6 as a Crucial Mediator
por: He, Hang, et al.
Publicado: (2022) -
Impact of CRISPR/Cas9-Mediated CD73 Knockout in Pancreatic Cancer
por: Zhang, Jinping, et al.
Publicado: (2023) -
Genome-Wide CRISPR Screening Identifies DCK and CCNL1 as Genes That Contribute to Gemcitabine Resistance in Pancreatic Cancer
por: Yang, Hai, et al.
Publicado: (2022) -
An m5C methylation regulator-associated signature predicts prognosis and therapy response in pancreatic cancer
por: Yun, Duo, et al.
Publicado: (2022)